Most patients are diagnosed with advanced non-small-cell lung cancer (NSCLC) [1], for which the current first-line treatment decisions are based on the presence of genetic aberrations, including the epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), UR2 sarcoma virus oncogene homolog 1 (ROS1), B-Raf proto-oncogene serine/threonine kinase (BRAF), Kirsten rat sarcoma virus (KRAS), and neurotrophic tropomyosin-related kinases (NTRK), amongst other targetable mutations [3]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.